News

#NACFC2016 – Kalydeco Improves Weight, Pulmonary Function in CF Patients with Pancreatic Insufficiency

In a recent presentation, researchers showed how Kalydeco (ivacaftor) is an effective therapy in cystic fibrosis (CF) patients with pancreatic insufficiency, improving the patients’ pulmonary function and weight, along with other clinical parameters. The presentation, “Improvement in weight, pulmonary function and other outcomes with 3-month Ivacaftor treatment differed by exocrine pancreatic…

#NACFC2016 – Catabasis to Present Data on Potential Treatment for CFTR and Bacterial Infection

Catabasis Pharmaceuticals announced that it will present data on CAT-5571, its investigational oral treatment for cystic fibrosis (CF). The drug has potential effectiveness both on improving the working of the cystic fibrosis transmembrane conductance regulator (CFTR), and in treating Pseudomonas aeruginosa infection. The data will be presented at the 30th Annual North American Cystic Fibrosis…

Resunab Named an Orphan Drug as Potential CF Treatment in Europe

Corbus Pharmaceuticals announced that the European Medicines Agency (EMA) has designated the company’s synthetic oral endocannabinoid-mimetic, Resunab (JBT-101), an orphan drug as a potential treatment for people with cystic fibrosis (CF). Resunab, which is currently being evaluated in a Phase 2 clinical trial in CF patients, preferentially binds to the CB2 receptor…